Obach, Victor
Velasco, Fernando
Alvarez Escudero, Rocio
Martín Bujanda, María
Aranceta, Sonsoles
Fabregat, Neus
Marco, Teresa
Ruisanchez, Aintzine
Roncero, Natalia
Mínguez-Olaondo, Ane
Ruibal, Marta
Guisado-Alonso, Daniel
Moreira, Antia
Cuadrado-Godia, Elisa
Echeverria, Amaya
Kortazar Zubizarreta, Izaro
López-Bravo, Alba
Riesco, Nuria
González-Fernández, Lucia
Pola, Nuria
Manera, Paula
Guerrero-Peral, Ángel Luis
Oterino Duran, Agustín
González-Osorio, Yésica
Armand, Rosario
Fernández-Fernández, Santiago
García-Azorín, David
García-Moncó, Juan Carlos
Article History
Received: 11 October 2023
Accepted: 9 November 2023
First Online: 22 November 2023
Declarations
:
: The study protocol was approved by the ethics committee of Hospital Clinic, Barcelona, Spain. Register number HCB/2021/1327 and written informed consent was obtained from all participants.
: Not applicable.
: Within the past 24 months, VO has received Speaker/travel grants/ clinical trials from Teva, Abbvie, Eli Lilly, Lundbeck, Pfizer and Biohaven. ALG has received research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Spain. Speaker/travel grants/ clinical trials from Teva, Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Biohaven. DGA has received research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Spain. Speaker/travel grants/ clinical trials from Teva, Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Biohaven. The remaining authors report no competing interests.